HomeCompareMAV vs JNJ

MAV vs JNJ: Dividend Comparison 2026

MAV yields 4.02% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAV wins by $2.5K in total portfolio value
10 years
MAV
MAV
● Live price
4.02%
Share price
$8.08
Annual div
$0.33
5Y div CAGR
-15.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.5K
Annual income
$83.08
Full MAV calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — MAV vs JNJ

📍 MAV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMAVJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MAV + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MAV pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MAV
Annual income on $10K today (after 15% tax)
$341.89/yr
After 10yr DRIP, annual income (after tax)
$70.62/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $632.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MAV + JNJ for your $10,000?

MAV: 50%JNJ: 50%
100% JNJ50/50100% MAV
Portfolio after 10yr
$21.3K
Annual income
$455.43/yr
Blended yield
2.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MAV
No analyst data
Altman Z
2.2
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MAV buys
0
JNJ buys
0
No recent congressional trades found for MAV or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMAVJNJ
Forward yield4.02%3.36%
Annual dividend / share$0.33$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR-15.7%5.8%
Portfolio after 10y$22.5K$20.0K
Annual income after 10y$83.08$827.78
Total dividends collected$1.9K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MAV vs JNJ ($10,000, DRIP)

YearMAV PortfolioMAV Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,039$339.08$10,676$355.77+$363.00MAV
2$12,107$294.90$11,407$389.39+$700.00MAV
3$13,209$254.81$12,198$426.53+$1.0KMAV
4$14,353$219.03$13,056$467.62+$1.3KMAV
5$15,545$187.50$13,987$513.12+$1.6KMAV
6$16,793$159.99$14,998$563.56+$1.8KMAV
7$18,105$136.17$16,098$619.52+$2.0KMAV
8$19,488$115.66$17,295$681.69+$2.2KMAV
9$20,950$98.09$18,599$750.82+$2.4KMAV
10$22,499$83.08$20,022$827.78+$2.5KMAV

MAV vs JNJ: Complete Analysis 2026

MAVStock

Pioneer Municipal High Income Advantage Fund, Inc. is a closed ended fixed income mutual fund launched and managed by Pioneer Investment Management, Inc. The fund invests in the fixed income markets of the United States. It invests primarily in municipal bonds. The fund benchmarks the performance of its portfolio against the Barclays Capital High Yield Municipal Bond Index and the Barclays Capital Municipal Bond Index. It was formerly known as Pioneer Municipal Advantage Trust. Pioneer Municipal High Income Advantage Fund, Inc. was formed on August 6, 2003 and is domiciled in the United States.

Full MAV Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this MAV vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MAV vs SCHDMAV vs JEPIMAV vs OMAV vs KOMAV vs MAINMAV vs ABBVMAV vs MRKMAV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.